HomeNewsBusinessMarketsEarnings to improve in 2-3 quarters; like NBFCs: Dolat Capital

Earnings to improve in 2-3 quarters; like NBFCs: Dolat Capital

While NBFCs are improving, banks are still reeling under stressed corporate cycle, says Amit Khurana, Co- Head Equities & Research, Dolat Capital Market.

June 02, 2016 / 13:40 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

Most of the important parameters are turning positive for the economy, says Amit Khurana, Co- Head Equities & Research, Dolat Capital Market. “Trajectory, now, is positively set,” he says. With expectations of economic growth, earnings too are expected to improve in another two to three quarters.Visibility is now improving for non-banking finance companies (NBFCs). Once economy improves, the space will see growth. However, banks are still impacted by stressed corporate cycle. Consumer side is slightly better, he says. Discussing stocks, Khurana recommends Coal India despite no visible volume growth in the company. Amongst oil marketing companies, he is bullish on Indian Oil Corporation and BPCL. Downstream companies are expected to benefit more than OMCs, he says. Khurana is also structurally positive on ITC, but says current valuation is expensive. He expects the stock to outperform its peers. Below is the verbatim transcript of Amit Khurana's interview with Ekta Batra & Anuj Singhal on CNBC-TV18.

Anuj: Start with Sun Pharmaceutical Industries and the fact that we have seen so much derating in the stock. Are you tempted to buy the stock at current valuation?

A: I wish I was but it doesn't look like. The guidance was disappointing and the first half, which may still be supported by the products launches that they had recently and that might have a spill over effect for the first quarter at least and partially for the second quarter. Things do not look that good for the company on overall portfolio basis, so I would still keep a wait and watch signal on that and look out how the first half pans out and how the visibility on critical issues especially the Food and Drug Administration (FDA) relating issues work out. We have seen a lot of challenges for the company and per se for the pharma as a sector, I would still be wary of buying the stock at these lower levels even then.

Story continues below Advertisement

Ekta: What is your sense in terms of how the FY17 picture might change for Coal India and would you be a buyer?

A: Their ability to take the price hike probably reflecting that the decisions are now being made on commercial level rather than just whims and fancies of any particular entity, but the critical issue here is volume growth. My concern remains that the volume growth has not yet picked up in terms of despatches number. If that shows signs of a turnaround, the stock has a potential to outperform over a medium-term. Having said that even otherwise in spite of volume growth muted the dividend yield, the overall defensive nature of the stock definitely encourages one to look at it. So I would look at it more from a positive bias and top it up with the price hike that they have taken. If they can now ramp up the volume part of it, the stock could be in for some very interesting times ahead and could outperform the market.